Sawai Group Holdings Co., Ltd. (TYO:4887)

Japan · Delayed Price · Currency is JPY

1,632.00

-7.50 (-0.46%)

Aug 14, 2026, 3:30 PM JST

-18.30% (1Y)

Market Cap	188.47B -18.3%
Revenue (ttm)	203.79B +4.9%
Net Income	7.98B -35.4%
EPS	68.85 -32.8%
Shares Out	115.49M
PE Ratio	19.81
Forward PE	10.25
Dividend	56.00 (3.43%)
Ex-Dividend Date	Sep 29, 2026

Volume	683,800
Open	1,636.50
Previous Close	1,639.50
Day's Range	1,621.50 - 1,641.50
52-Week Range	1,550.50 - 2,447.00
Beta	0.03
Analysts	Buy
Price Target	2,193.33 (+34.4%)
Earnings Date	Aug 10, 2026

About Sawai Group Holdings

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research and development, manufacture, and marketing of generic pharmaceuticals. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms for various therapeutic areas comprising cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, urogenital organs and... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1929

Employees 3,630

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 4887

Full Company Profile

Financial Performance

In fiscal year 2026, Sawai Group Holdings's revenue was 201.68 billion, an increase of 6.69% compared to the previous year's 189.02 billion. Earnings were 10.44 billion, a decrease of -12.79%.

Financial Statements

Analyst Summary

According to 9 analysts, the average rating for 4887 stock is "Buy." The 12-month stock price target is ¥2,193, which is an increase of 34.40% from the latest price.

Price Target

¥2,193

(34.40% upside)

Analyst Consensus: Buy

Stock Forecasts

News

Sawai Group Holdings Quarterly report: Q1 2027

Sawai Group Holdings has published its Q1 2027 quarterly earnings report on August 10, 2026.

5 days ago - Filings

Sawai Group Holdings Slides: Q1 2027

Sawai Group Holdings has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 10, 2026.

5 days ago - Filings

Sawai Group Holdings Transcript: Transcript

Revenue and profits grew year-over-year, driven by higher sales prices and lifted shipment restrictions, while one-time gains from asset sales boosted net income. FY 2025 guidance anticipates continued revenue and profit growth, despite drug price pressures and rising costs.

15 days ago - Transcripts

Sawai Group Holdings Transcript: Transcript

Revenue and profits grew year-over-year, aided by a U.S. affiliate share sale and land sale proceeds. The outlook targets further profit growth via new products and increased production, with a 4% full-year revenue increase forecast.

15 days ago - Transcripts

Sawai Group Holdings Transcript: Transcript

Revenue grew 6.7% year-on-year, driven by new and existing products, while operating profit surged due to the absence of litigation costs. FY 2026 forecasts anticipate continued growth in revenue and profit, supported by new product launches and expanded production capacity.

15 days ago - Transcripts

Sawai Group Holdings Transcript: Transcript

Revenue rose 12.5% year-over-year, but operating profit fell 27.4% due to a major patent settlement. Core operating profit increased 9.5%, and full year guidance was revised as production volume lags initial targets.

15 days ago - Transcripts